CCM
BMRN icon

Crossvault Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crossvault Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-20,960
Closed -$1.84M – 62
2017
Q1 		$1.84M Buy
20,960
+365
+2% +$32.5K 1.14% 31
2016
Q4 		$1.71M Sell
20,595
-750
-4% -$64.5K 1.15% 31
2016
Q3 		$1.98M Buy
21,345
+3,275
+18% +$308K 1.38% 30
2016
Q2 		$1.41M Sell
18,070
-75
-0.4% -$6.38K 0.99% 30
2016
Q1 		$1.5M Buy
18,145
+3,740
+26% +$304K 1.1% 30
2015
Q4 		$1.51M Buy
14,405
+1,895
+15% +$198K 1.07% 32
2015
Q3 		$1.32M Buy
12,510
+5,435
+77% +$726K 1.03% 31
2015
Q2 		$968K Buy
7,075
+975
+16% +$121K 0.77% 32
2015
Q1 		$760K Sell
6,100
-8,680
-59% -$920K 0.61% 39
2014
Q4 		$1.34M Sell
14,780
-225
-1% -$18.7K 1.17% 31
2014
Q3 		$1.08M Buy
15,005
+1,747
+13% +$115K 1.02% 31
2014
Q2 		$825K Sell
13,258
-525
-4% -$31.7K 0.77% 37
2014
Q1 		$940K Buy
13,783
+1,500
+12% +$111K 0.91% 34
2013
Q4 		$864K Buy
+12,283
New +$834K 0.83% 35

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crossvault Capital Management's BMRN Position: Q2 2017 in Review

Crossvault Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 20,960 shares — an estimated $1.84M sold.

Crossvault Capital Management first reported a position in BMRN in Q4 2013 and held it in 14 quarters. The position peaked at $1.98M in Q3 2016. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Crossvault Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Crossvault Capital Management sold 20,960 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $1.84M.
  • Crossvault Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 14 quarters.
  • Crossvault Capital Management's BioMarin Pharmaceuticals position peaked at $1.98M in Q3 2016.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Crossvault Capital Management's 13F filing for Q2 2017, filed 20 Jul 2017.